{"product_id":"understanding-lymph-node-management-in-breast-cancer-what-every-patient-should-know","title":"Understanding Lymph Node Management in Breast Cancer: What Every Patient Should Know","description":"\u003cp\u003eBreast cancer most commonly spreads first to the lymph nodes under the arm (axillary lymph nodes) and in surrounding areas, and how doctors evaluate and treat these nodes has changed dramatically in recent decades. This article explains the three main lymph node groups at risk (axillary, internal mammary, and supraclavicular), how doctors assess the armpit before and during surgery, and the modern, less invasive approaches—such as sentinel lymph node biopsy (SLNB) and targeted axillary dissection (TAD)—that spare many women from the more extensive axillary lymph node dissection (ALND). Drawing on landmark trials including NSABP B-04, Z0011, AMAROS, and OTOASOR, the evidence shows that many women with limited lymph node involvement can safely avoid complete dissection without compromising their survival, while still achieving excellent control of cancer in the armpit region.\u003c\/p\u003e\n\n\u003ch1\u003eUnderstanding Lymph Node Management in Breast Cancer: What Every Patient Should Know\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#introduction\"\u003eIntroduction: Why Lymph Nodes Matter in Breast Cancer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#regional-lymph-nodes\"\u003eThe Regional Lymph Nodes: Where Breast Cancer Spreads First\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#axillary-lymph-nodes\"\u003eAxillary Lymph Nodes (Under the Armpit)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#internal-mammary-nodes\"\u003eInternal Mammary Lymph Nodes (Along the Breastbone)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#supraclavicular-nodes\"\u003eSupraclavicular Lymph Nodes (Above the Collarbone)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#axillary-evaluation\"\u003eHow Doctors Evaluate the Axilla\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#physical-examination\"\u003ePhysical Examination\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#axillary-ultrasound\"\u003eAxillary Ultrasound\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#needle-biopsy\"\u003ePercutaneous Needle Biopsy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#axillary-management\"\u003eManaging the Axilla: Treatment Options\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#benefit-of-treatment\"\u003eThe Benefit of Axillary Treatment\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatment-comparison\"\u003eComparing Treatment Modalities\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#no-neoadjuvant\"\u003ePatients Who Do Not Receive Neoadjuvant Therapy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Current Evidence\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eThe armpit lymph nodes receive about 85 percent of breast lymphatic drainage, making them the first and most common site of spread.\u003c\/li\u003e\n\u003cli\u003ePhysical exam alone misses many positive lymph nodes; in the NSABP B-32 trial, 26 percent of clinically negative patients had node-positive disease.\u003c\/li\u003e\n\u003cli\u003eTrials Z0011, AMAROS, and OTOASOR show that patients with one or two positive sentinel nodes can safely skip ALND and use radiation instead, with similar survival.\u003c\/li\u003e\n\u003cli\u003eTargeted axillary dissection, which removes a marked positive node, reduced the sentinel node biopsy false negative rate from 12.6 percent to 6.8 percent in the Z1071 trial.\u003c\/li\u003e\n\u003cli\u003eALND causes more lymphedema than axillary radiation, so combining both is generally avoided unless the risk of recurrence is very high.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"introduction\"\u003eIntroduction: Why Lymph Nodes Matter in Breast Cancer\u003c\/h2\u003e\n\u003cp\u003eWhen breast cancer spreads beyond the breast itself, it most often travels first through the lymphatic system—a network of vessels and small, bean-shaped organs called lymph nodes that help filter fluid and fight infection. The lymphatic drainage areas of the breast include the axillary (armpit), internal mammary (along the breastbone), and supraclavicular (above the collarbone) lymph node groups. These are the nodes most likely to contain cancer cells in patients with metastatic breast cancer.\u003c\/p\u003e\n\u003cp\u003eThis article reviews the risk of breast cancer spreading to these regional lymph nodes, how doctors assess the armpit before surgery, and the current indications for axillary lymph node dissection versus axillary radiation. Understanding these concepts can help patients participate more confidently in decisions about their care.\u003c\/p\u003e\n\n\u003ch2 id=\"regional-lymph-nodes\"\u003eThe Regional Lymph Nodes: Where Breast Cancer Spreads First\u003c\/h2\u003e\n\u003cp\u003eThe axillary lymph nodes receive the majority of lymphatic drainage from all quadrants of the breast—approximately \u003cstrong\u003e85 percent\u003c\/strong\u003e. The remaining drainage goes to the internal mammary, infraclavicular (below the collarbone), and supraclavicular lymph nodes.\u003c\/p\u003e\n\u003cp\u003eSeveral factors influence whether cancer has reached these nodes, including tumor size, tumor location, and specific microscopic features such as grade, lymphatic invasion, and hormone receptor status.\u003c\/p\u003e\n\n\u003ch2 id=\"axillary-lymph-nodes\"\u003eAxillary Lymph Nodes (Under the Armpit)\u003c\/h2\u003e\n\u003cp\u003eThe likelihood that cancer has spread to the axillary lymph nodes (ALNs) depends on several tumor characteristics:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTumor size:\u003c\/strong\u003e In general, larger primary tumors are associated with a higher likelihood of ALN involvement, although this can vary by tumor subtype. In a series of \u003cstrong\u003e6,800 women\u003c\/strong\u003e diagnosed with invasive breast cancer after screening mammography, the incidence rate of ALN involvement increased steadily with tumor size.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSmall tumors can still spread:\u003c\/strong\u003e ALN metastases are relatively common even with invasive breast cancers measuring ≤1 cm. In a report of \u003cstrong\u003e919 women\u003c\/strong\u003e who underwent ALN dissection, metastases were detected in \u003cstrong\u003e16 percent\u003c\/strong\u003e of those with T1a tumors (tumor size 0.1 to 0.5 cm) and \u003cstrong\u003e19 percent\u003c\/strong\u003e of those with T1b tumors (tumor size 0.5 to 1.0 cm).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTumor location:\u003c\/strong\u003e Tumors in the lateral (outer) portion of the breast are more likely to spread to the armpit nodes than tumors in the medial (inner) portion. In a study of \u003cstrong\u003e1,671 early-stage breast cancers\u003c\/strong\u003e, the odds ratio of a lateral tumor having axillary metastasis was \u003cstrong\u003e1.33 (95% CI 0.95–1.87)\u003c\/strong\u003e compared with a medial tumor. The most likely explanation is that some medial tumors drain preferentially to the internal mammary nodes instead.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHistologic grade:\u003c\/strong\u003e Grade 1 tumors (slow-growing, well-differentiated) have a significantly lower rate of axillary metastases than grade 2 or 3 tumors. Using data from the Surveillance, Epidemiology, and End Results (SEER) database, the incidence of ALN involvement in patients with grade 1 versus grade 3 tumors of similar size was \u003cstrong\u003e3.4 percent versus 21 percent\u003c\/strong\u003e, respectively.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLow-risk tumor types:\u003c\/strong\u003e Tumors associated with a less than \u003cstrong\u003e5 percent risk\u003c\/strong\u003e of axillary metastases include those with a single focus of microinvasion, \u0026lt;5 mm grade 1 tumors without lymphatic invasion, and pure mucinous or pure tubular carcinomas smaller than 1 cm.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTumor subtype:\u003c\/strong\u003e After adjusting for size, some subtypes (e.g., HER2-positive and triple-negative) have higher node positivity rates than others (e.g., luminal\/hormone-receptor positive).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDetection method:\u003c\/strong\u003e Across all size categories, patients whose invasive tumors are detected by screening mammography are more likely to have pathologically negative lymph nodes than those whose tumors are found clinically.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"internal-mammary-nodes\"\u003eInternal Mammary Lymph Nodes (Along the Breastbone)\u003c\/h2\u003e\n\u003cp\u003eThe internal mammary nodes (IMNs) receive drainage from all quadrants of the breast, but medial tumors have a significantly higher rate of IMN metastases. Although the IMN chain extends from the fifth intercostal space to the retroclavicular region, nodes in the upper three interspaces are most likely to contain metastases.\u003c\/p\u003e\n\u003cp\u003eIsolated IMN metastases are infrequent; more often, the axillary nodes are involved as well. In a report of over \u003cstrong\u003e7,000 cases\u003c\/strong\u003e in which both IMNs and ALNs were examined, IMN metastases were detected in \u003cstrong\u003e22 percent\u003c\/strong\u003e of patients, but fewer than \u003cstrong\u003e5 percent\u003c\/strong\u003e of the node-positive patients had IMN-only disease. Isolated IMN involvement was more frequent for medial than lateral tumors—\u003cstrong\u003e7.6 percent versus 2.9 percent\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eRegarding imaging, there are no convincing data that routine imaging of the IMNs is needed in clinically node-negative patients. They may be visualized incidentally during staging PET or chest CT scans, and the results can change the patient's nodal stage and potentially impact surgical and radiation treatment plans.\u003c\/p\u003e\n\u003cp\u003eManagement of the IMNs remains somewhat controversial:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSentinel lymph node biopsy:\u003c\/strong\u003e Dissection of the IMNs during SLNB is considered investigational. Using standard technique, IMNs are only visualized in about \u003cstrong\u003e20 percent\u003c\/strong\u003e of patients during SLNB. An IMN is rarely positive if an axillary sentinel node is negative. Since the IMN status rarely changes management, very few surgeons perform SLNB of the IMN or attempt to identify these nodes preoperatively with lymphoscintigraphy. Potential complications of IMN biopsy include pleural effusion (fluid around the lung) and injury to the internal mammary artery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRadical dissection:\u003c\/strong\u003e Following four early (1960s) randomized trials showing no survival benefit from extended mastectomy (which included IMN dissection) compared with radical or modified radical mastectomy, routine dissection of the IMNs was abandoned. In addition, the widespread use of adjuvant systemic therapy (chemotherapy, hormonal therapy, or targeted therapy after surgery) has diminished the importance of the IMNs in clinical care.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRadiation therapy:\u003c\/strong\u003e For women receiving adjuvant regional radiation therapy—either after breast-conserving surgery or with postmastectomy radiation—radiation of the IMNs is generally included. However, an individualized approach is necessary, taking into account the patient's risk of IMN involvement, her anatomy, and the ability to protect critical structures like the heart from the radiation field.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"supraclavicular-nodes\"\u003eSupraclavicular Lymph Nodes (Above the Collarbone)\u003c\/h2\u003e\n\u003cp\u003eSupraclavicular nodal metastases are usually associated with extensive axillary node involvement and are rare without it. In a series of \u003cstrong\u003e274 women\u003c\/strong\u003e undergoing routine supraclavicular dissection, supraclavicular metastases were found in \u003cstrong\u003e18 percent\u003c\/strong\u003e of those with axillary metastases but only \u003cstrong\u003e0.7 percent\u003c\/strong\u003e of those without.\u003c\/p\u003e\n\u003cp\u003eThese metastases represent locally advanced disease. Nonetheless, curative treatment is possible with aggressive multimodality treatment—typically consisting of neoadjuvant systemic therapy (treatment given before surgery), surgery, possible additional adjuvant systemic therapy, and radiation.\u003c\/p\u003e\n\n\u003ch2 id=\"axillary-evaluation\"\u003eHow Doctors Evaluate the Axilla\u003c\/h2\u003e\n\u003cp\u003eBefore deciding on treatment, the armpit area can be evaluated using three complementary tools: physical examination, axillary ultrasound, and\/or percutaneous needle biopsy (either core needle biopsy [CNB] or fine needle aspiration [FNA]). The optimal pathway depends on the tumor size and its pathologic features, including receptor status, because these factors influence whether neoadjuvant systemic treatment will be recommended.\u003c\/p\u003e\n\n\u003ch2 id=\"physical-examination\"\u003ePhysical Examination\u003c\/h2\u003e\n\u003cp\u003eAll patients undergo a physical examination of the axilla, but this exam is neither sensitive nor reliable on its own. Metastatic lymph nodes are often not palpable, and benign reactive lymph nodes may be mistaken for metastases. The positive predictive value of clinical palpation—the likelihood of finding axillary metastases when the exam is suspicious—ranges from \u003cstrong\u003e61 to 84 percent\u003c\/strong\u003e. The negative predictive value—the likelihood of no metastases when the exam is normal—is only \u003cstrong\u003e50 to 60 percent\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eIn the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 sentinel node trial, among patients with clinically negative axillary nodes, the node-positive rate was \u003cstrong\u003e26 percent\u003c\/strong\u003e. This means that about one in four patients with a normal-feeling armpit still had cancer in their lymph nodes.\u003c\/p\u003e\n\n\u003ch2 id=\"axillary-ultrasound\"\u003eAxillary Ultrasound\u003c\/h2\u003e\n\u003cp\u003eAxillary ultrasound is an effective screening method for detecting nodal metastasis in patients with invasive breast cancer. However, its accuracy is operator-dependent, so results can vary between centers.\u003c\/p\u003e\n\u003cp\u003eThe use of axillary ultrasound in newly diagnosed patients varies. Some experts routinely perform it in all patients with invasive breast cancer; others reserve it for patients with palpable nodes or those planning neoadjuvant chemotherapy.\u003c\/p\u003e\n\u003cp\u003eFor patients \u003cem\u003enot\u003c\/em\u003e planning neoadjuvant chemotherapy, the benefit of preoperative axillary ultrasound is debated:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProponents\u003c\/strong\u003e argue that ultrasound staging can identify patients with a high axillary disease burden—defined as ≥3 metastatic nodes, extranodal extension, or level III nodes—who may go directly to ALND. In a retrospective study of patients with only one metastatic node on preoperative ultrasound who met the Z0011 criteria, ultrasound had a sensitivity and negative predictive value of \u003cstrong\u003e92 percent\u003c\/strong\u003e and a false negative rate of \u003cstrong\u003e8 percent\u003c\/strong\u003e—performance comparable to that of SLNB.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOpponents\u003c\/strong\u003e argue that early breast cancer patients are unlikely to have many involved nodes, that ultrasound cannot reliably distinguish between one or two positive nodes versus three or more, and that it does not add sufficient information beyond SLNB to change management.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThree ongoing trials—the SOUND trial (NCT02167490), the INSEMA trial, and the BOOG 2013-08 trial—are evaluating whether patients with a negative axillary ultrasound even need additional axillary surgery at all. Their results may further de-escalate axillary surgery for breast cancer.\u003c\/p\u003e\n\u003cp\u003eFor patients \u003cem\u003eplanning\u003c\/em\u003e neoadjuvant chemotherapy, ultrasound offers a clear benefit: it permits \u003cstrong\u003etargeted axillary dissection\u003c\/strong\u003e by identifying, guiding biopsy of, and marking any positive nodes with a clip or tattoo before chemotherapy begins. In the Z1071 trial, targeted axillary dissection reduced the false negative rate of SLNB from \u003cstrong\u003e12.6 percent to 6.8 percent\u003c\/strong\u003e in patients with positive axillary nodes undergoing neoadjuvant treatment.\u003c\/p\u003e\n\n\u003ch2 id=\"needle-biopsy\"\u003ePercutaneous Needle Biopsy\u003c\/h2\u003e\n\u003cp\u003eAbnormal lymph nodes found on axillary ultrasound should undergo needle biopsy for pathologic analysis. Both core needle biopsy (CNB) and fine needle aspiration (FNA) can be performed percutaneously under ultrasound guidance. However, until more data become available, a needle biopsy of an abnormal node does not replace surgical evaluation—SLNB is still required in most patients with breast cancer.\u003c\/p\u003e\n\n\u003ch2 id=\"axillary-management\"\u003eManaging the Axilla: Treatment Options\u003c\/h2\u003e\n\u003cp\u003eThe decision to give neoadjuvant chemotherapy, endocrine therapy, or immunotherapy depends on the hormone receptor and HER2 status of the cancer and its stage. The overall approach to the axilla depends largely on whether the patient received neoadjuvant treatment.\u003c\/p\u003e\n\n\u003ch2 id=\"benefit-of-treatment\"\u003eThe Benefit of Axillary Treatment\u003c\/h2\u003e\n\u003cp\u003eAxillary treatment improves regional disease control—that is, it reduces the chance that cancer will come back in the armpit area. However, with modern systemic treatments, there is no clear evidence that treating the axilla improves overall survival.\u003c\/p\u003e\n\u003cp\u003eThis was powerfully demonstrated in the landmark \u003cstrong\u003eNSABP B-04 trial\u003c\/strong\u003e, conducted from 1971 to 1974. In that study, clinically node-negative patients were randomly assigned to one of three treatments:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eTotal mastectomy with axillary lymph node dissection (ALND)\u003c\/li\u003e\n  \u003cli\u003eTotal mastectomy with regional radiation therapy (RT)\u003c\/li\u003e\n  \u003cli\u003eTotal mastectomy alone, with delayed ALND at the time of any recurrence\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eAlthough the 10-year survival was similar across all three groups, the axillary failure rate was significantly higher in women treated with mastectomy alone (\u003cstrong\u003e18 percent\u003c\/strong\u003e) compared with those receiving regional RT or initial ALND (\u003cstrong\u003e3.1 percent\u003c\/strong\u003e and \u003cstrong\u003e1.4 percent\u003c\/strong\u003e, respectively). The authors note that the true failure rate in the delayed-ALND group was probably even higher than 18 percent, because inoperable recurrences and recurrences that happened alongside distant metastases were excluded from the calculation.\u003c\/p\u003e\n\u003cp\u003eIt is important to recognize the context of the B-04 era: mammographic screening was neither widespread nor as sophisticated, adjuvant systemic therapy was less refined, and the average tumor size was generally larger than what is found today. Since the likelihood of subclinical axillary metastases increases with tumor size, experts anticipate that axillary failure rates without dissection or radiation today would be significantly lower—especially with modern systemic regimens. Indeed, in the more recent Z0011 trial, the axillary relapse rate was just \u003cstrong\u003e0.5 percent\u003c\/strong\u003e with ALND and \u003cstrong\u003e1 percent\u003c\/strong\u003e with SLNB alone.\u003c\/p\u003e\n\n\u003ch2 id=\"treatment-comparison\"\u003eComparing Treatment Modalities\u003c\/h2\u003e\n\u003cp\u003eThere are two main modalities of axillary treatment: surgery (sentinel lymph node biopsy, targeted axillary dissection, or axillary lymph node dissection) and radiation (regional radiotherapy). Given randomized trial data showing that many women with limited or no sentinel node involvement can safely omit ALND and be treated with radiation alone, this has become the standard approach for women who meet the \"Z0011 criteria.\"\u003c\/p\u003e\n\u003cp\u003eBoth surgery and radiation to the armpit increase the risk of long-term swelling of the arm on the same side (ipsilateral lymphedema), so using both together is often avoided except in very high-risk situations.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSentinel lymph node biopsy (SLNB):\u003c\/strong\u003e In patients with clinically node-negative early breast cancer, SLNB identifies those with limited or no axillary node involvement, allowing them to avoid more extensive surgery. The decision to proceed with ALND is based on the SLNB results, primary tumor size, and other factors.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTargeted axillary dissection (TAD):\u003c\/strong\u003e TAD is a newer staging technique that removes any biopsy-proven positive axillary nodes (previously marked with a clip or tattoo before neoadjuvant chemotherapy) in addition to performing SLNB. TAD targets the removal of positive nodes while minimizing the morbidity of a full dissection. In a meta-analysis of over \u003cstrong\u003e3,000 patients\u003c\/strong\u003e, the pooled success rate of identifying and retrieving a marked node was \u003cstrong\u003e90.0 percent (95% CI 85.1–95.1)\u003c\/strong\u003e. Compared with ALND across 13 studies, TAD was associated with a false negative rate of \u003cstrong\u003e5.18 percent (95% CI 3.41–7.54)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAxillary lymph node dissection (ALND):\u003c\/strong\u003e ALND is the traditional and most complete surgical removal of lymph nodes from the armpit. It provides excellent disease control and important prognostic information, and it guides treatment selection. However, the anatomic disruption it causes can lead to lymphedema, nerve injury, and shoulder dysfunction, all of which compromise function and quality of life. ALND was once a routine part of breast cancer care, but SLNB is now the standard initial approach for women with early breast cancer who meet the Z0011 criteria.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRegional radiotherapy:\u003c\/strong\u003e Standard whole breast radiation after lumpectomy—or postmastectomy radiation—includes two tangential radiation fields to the breast or chest wall, which generally covers the lower portion of the axillary nodes. Full regional RT uses an additional third (and sometimes fourth) field to treat the supraclavicular, infraclavicular, and upper axillary nodes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSeveral randomized trials have directly compared outcomes in women treated with ALND versus regional RT for early-stage breast cancer. All have shown low rates of axillary failure after either approach and similar long-term survival—allowing many women to avoid ALND by incorporating regional RT instead.\u003c\/p\u003e\n\n\u003ch3\u003eThe AMAROS Trial\u003c\/h3\u003e\n\u003cp\u003eReported in 2014, the After Mapping of the Axilla: Radiotherapy or Surgery (AMAROS) trial was a large multi-institutional study that included \u003cstrong\u003e4,806 patients\u003c\/strong\u003e with T1 or T2 unifocal invasive breast cancer and no palpable axillary lymphadenopathy. Among the \u003cstrong\u003e1,425 patients\u003c\/strong\u003e found to have positive sentinel nodes on SLNB:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e744\u003c\/strong\u003e were randomly assigned to receive ALND\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e681\u003c\/strong\u003e were randomly assigned to receive axillary radiotherapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eNinety-five percent of patients in both groups had one or two positive sentinel nodes. At five years, the axillary recurrence rate was \u003cstrong\u003e0.43 percent (95% CI 0–0.92)\u003c\/strong\u003e in the ALND group and \u003cstrong\u003e1.19 percent (95% CI 0.31–2.08)\u003c\/strong\u003e in the radiation group. There were no statistically significant differences in survival between the treatment groups. However, lymphedema was reported significantly more often after ALND than after axillary radiation at one, three, and five years.\u003c\/p\u003e\n\u003cp\u003eAt 10-year follow-up, the axillary recurrence rate remained low and comparable: \u003cstrong\u003e0.93 percent\u003c\/strong\u003e in the ALND group (7 of 744 patients) versus \u003cstrong\u003e1.82 percent\u003c\/strong\u003e in the radiation group (11 of 681 patients). Distant metastasis-free survival and overall survival were similar. Interestingly, the trial found that more second primary cancers developed in the patients treated with axillary radiotherapy (\u003cstrong\u003e11.0 percent versus 7.7 percent, p = 0.035\u003c\/strong\u003e); some of these were cancers in the opposite breast, and it remains unclear how much of this increase was due to radiation versus chance alone.\u003c\/p\u003e\n\n\u003ch3\u003eThe OTOASOR Trial\u003c\/h3\u003e\n\u003cp\u003eIn the OTOASOR trial, \u003cstrong\u003e474 patients\u003c\/strong\u003e with tumors ≤3 cm, clinically node-negative disease, and a positive sentinel node biopsy were randomly assigned to completion ALND versus axillary radiation. There was no statistically significant difference between the two groups in axillary recurrence or overall survival—either at 40 months (axillary recurrence \u003cstrong\u003e0.82 percent\u003c\/strong\u003e for ALND versus \u003cstrong\u003e1.3 percent\u003c\/strong\u003e for radiation) or at 97 months (axillary recurrence \u003cstrong\u003e2 percent\u003c\/strong\u003e versus \u003cstrong\u003e1.7 percent\u003c\/strong\u003e; overall survival \u003cstrong\u003e77.9 percent\u003c\/strong\u003e versus \u003cstrong\u003e84.8 percent\u003c\/strong\u003e; disease-free survival \u003cstrong\u003e72.1 percent\u003c\/strong\u003e versus \u003cstrong\u003e77.4 percent\u003c\/strong\u003e).\u003c\/p\u003e\n\n\u003ch2 id=\"no-neoadjuvant\"\u003ePatients Who Do Not Receive Neoadjuvant Therapy\u003c\/h2\u003e\n\u003cp\u003eMost patients without known axillary metastases before surgery undergo SLNB at the time of their primary breast surgery. SLNB reliably distinguishes between patients who require ALND and those who do not. For patients who are found to have no axillary metastasis on preoperative evaluation, SLNB is the standard method of axillary staging.\u003c\/p\u003e\n\u003cp\u003eThe choice of whether to proceed with ALND or regional nodal irradiation—or both—after a positive SLNB depends on the extent of node involvement, the characteristics of the primary tumor, and the patient's overall treatment plan, guided by the randomized evidence summarized above.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications for Patients\u003c\/h2\u003e\n\u003cp\u003eFor patients facing a new breast cancer diagnosis, these findings translate into several important practical messages:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot every positive lymph node requires full removal.\u003c\/strong\u003e The Z0011, AMAROS, and OTOASOR trials collectively demonstrate that women with one or two positive sentinel nodes can safely skip ALND and be treated with radiation alone (or in some cases, with no further axillary treatment), with very low rates of recurrence and no loss of survival.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLymphedema risk is lower with less surgery.\u003c\/strong\u003e Since both surgery and radiation can cause arm swelling, combining them is avoided whenever possible. Avoiding ALND where safe helps preserve quality of life.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTargeted axillary dissection is a promising middle ground.\u003c\/strong\u003e For patients receiving chemotherapy before surgery, marking the positive node beforehand allows surgeons to remove it selectively—reducing false negative rates from 12.6 percent to 6.8 percent.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe internal mammary nodes rarely need separate treatment.\u003c\/strong\u003e Because isolated IMN involvement is uncommon (fewer than 5 percent of node-positive patients), and because systemic therapy is so effective, routine biopsy or dissection of these nodes has been abandoned.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSupraclavicular spread is not hopeless.\u003c\/strong\u003e Even when cancer reaches nodes above the collarbone, aggressive treatment with systemic therapy, surgery, and radiation can still be curative.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Current Evidence\u003c\/h2\u003e\n\u003cp\u003eIt is important to understand what this body of evidence cannot tell us. The B-04 trial reflects an era of larger tumors, less effective systemic therapy, and less sophisticated screening; its 18 percent axillary failure rate with mastectomy alone is likely far higher than what would be seen today. The AMAROS trial's finding of more second primary cancers in the radiation group is incompletely understood—it is unclear how much reflects the radiation itself versus chance. Additionally, ultrasound accuracy is operator-dependent, meaning its usefulness varies from center to center. Several ongoing trials (SOUND, INSEMA, and BOOG 2013-08) are still investigating whether some patients with a negative ultrasound can skip axillary surgery altogether, and their results will further refine these recommendations.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\u003cp\u003eBased on the current evidence, here is practical guidance for women navigating breast cancer treatment decisions:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk your surgeon about your specific risk factors.\u003c\/strong\u003e Tumor size, grade, location, and receptor status all influence the likelihood of lymph node involvement—and therefore the appropriate surgical plan.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand that a negative physical exam is not conclusive.\u003c\/strong\u003e Because clinical palpation misses many positive nodes (the node-positive rate in clinically negative patients was 26 percent in NSABP B-32), imaging and surgical staging play critical roles.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss whether axillary ultrasound will be performed.\u003c\/strong\u003e If you are planning neoadjuvant chemotherapy, ultrasound-guided biopsy with marking of any positive node is particularly valuable, as it enables targeted axillary dissection later.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf your sentinel node is positive with limited involvement, ask whether ALND can be avoided.\u003c\/strong\u003e The evidence strongly supports omitting ALND in many patients with one or two positive sentinel nodes, especially those meeting Z0011 criteria.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeigh the risks of lymphedema carefully.\u003c\/strong\u003e If both surgery and radiation to the armpit are being proposed, ask your care team about the specific reasons and risks, since combining them is generally avoided.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStay informed about clinical trials.\u003c\/strong\u003e The SOUND, INSEMA, and BOOG 2013-08 trials are testing whether even SLNB can be safely omitted in some patients with negative ultrasounds. Ask your oncologist whether any ongoing studies might be relevant to your situation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreat the whole picture.\u003c\/strong\u003e Axillary treatment improves regional control, but survival is driven predominantly by systemic treatment. Your chemotherapy, endocrine therapy, or HER2-targeted therapy is at least as important as the lymph node surgery in determining your long-term outcome.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat are the lymph nodes most likely to be affected when breast cancer spreads?\u003c\/h3\u003e\n\u003cp\u003eBreast cancer usually spreads first through the lymphatic system to three nearby lymph node groups: under the armpit (axillary), along the breastbone (internal mammary), and above the collarbone (supraclavicular). The armpit nodes receive most of the breast's drainage, about 85 percent, so they are the most common site of early spread.\u003c\/p\u003e\n\u003ch3\u003eHow do doctors check whether breast cancer has spread to the armpit lymph nodes?\u003c\/h3\u003e\n\u003cp\u003eDoctors use three tools: a physical exam, an axillary ultrasound, and a needle biopsy of any suspicious node. Physical exam alone is not reliable, missing many positive nodes. Ultrasound can spot abnormal nodes, and a needle biopsy confirms cancer. However, surgery with sentinel lymph node biopsy is still required for most patients to stage the armpit accurately.\u003c\/p\u003e\n\u003ch3\u003eWhat is sentinel lymph node biopsy (SLNB) and why is it done?\u003c\/h3\u003e\n\u003cp\u003eSentinel lymph node biopsy is a surgery that removes only the first few lymph nodes that receive drainage from the breast, called sentinel nodes. It identifies whether cancer has spread and whether more extensive surgery is needed. For patients with early breast cancer and no clinically positive nodes, SLNB is the standard method of staging the armpit, helping many avoid full dissection.\u003c\/p\u003e\n\u003ch3\u003eCan I avoid axillary lymph node dissection if my sentinel node is positive?\u003c\/h3\u003e\n\u003cp\u003eIn many cases, yes. Landmark trials like Z0011, AMAROS, and OTOASOR showed that women with one or two positive sentinel nodes can safely skip full axillary dissection and instead receive radiation alone, without harming survival. Your surgeon will consider your tumor size, extent of node involvement, and overall treatment plan to decide if ALND can be avoided.\u003c\/p\u003e\n\u003ch3\u003eWhat is targeted axillary dissection (TAD) and who might need it?\u003c\/h3\u003e\n\u003cp\u003eTargeted axillary dissection combines sentinel node biopsy with removal of any biopsy-proven positive lymph node that was marked with a clip or tattoo before chemotherapy. It is used for patients receiving neoadjuvant treatment. In a meta-analysis, TAD successfully retrieved the marked node 90 percent of the time, and it cut the false negative rate of sentinel biopsy from 12.6 percent to 6.8 percent.\u003c\/p\u003e\n\u003ch3\u003eWhat are the risks of axillary lymph node dissection?\u003c\/h3\u003e\n\u003cp\u003eAxillary lymph node dissection can cause lymphedema, nerve injury, and shoulder dysfunction, affecting quality of life. In trials, lymphedema was significantly more common after ALND than after axillary radiation. Because both surgery and radiation can cause arm swelling, doctors usually avoid using both together unless the risk of recurrence is very high, to preserve arm function.\u003c\/p\u003e\n\u003ch3\u003eWhy are internal mammary and supraclavicular lymph nodes rarely treated separately?\u003c\/h3\u003e\n\u003cp\u003eInternal mammary node spread is uncommon—fewer than 5 percent of node-positive patients have it alone—and systemic therapy is very effective, so routine biopsy or dissection of these nodes has been abandoned. Supraclavicular spread is rare without extensive axillary involvement and is treated with aggressive combination therapy, including systemic treatment, surgery, and radiation, which can still be curative.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Overview of management of the regional lymph nodes in breast cancer - UpToDate\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Seth P Harlow, MD; Donald L Weaver, MD\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSection Editors:\u003c\/strong\u003e Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C); Daniel F Hayes, MD; David E Wazer, MD\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDeputy Editors:\u003c\/strong\u003e Wenliang Chen, MD, PhD; Sadhna R Vora, MD\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e Literature review current through November 2022; topic last updated August 31, 2022.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eNote: This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace individualized medical advice from your oncology care team.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47458703081628,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/products\/understanding-lymph-node-management-in-breast-cancer-what-every-patient-should-know","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}